We continue to deliver on the promise we made when we began our turnaround in 1997 of achieving annual double digit earnings growth, ... Our results this quarter were again driven by strong growth in the U.S., where prescription sales increased 28 percent.
Our cholesterol franchise is pivotal and continues to gain share in the United States and other major markets.
Our cholesterol franchise continues to be a critical growth driver.
Looking ahead, we continue on track to build Schering- Plough into a company with the strength and breadth to deliver long-term high performance. We are moving from survive mode into thrive mode.
These changes are designed to further strengthen the global finance team, which continues to play an important role in the transformation of Schering- Plough.